Egetis Therapeutics Crecimiento futuro

Future controles de criterios 6/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Egetis Therapeutics de 85.4% y 67.1% por año respectivamente. Se prevé que el BPA crezca en un 87.7% al año. Se espera que la rentabilidad financiera sea de 38.5% en 3 años.

Información clave

98.2%

Tasa de crecimiento de los beneficios

98.5%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	40.7%
Tasa de crecimiento de los ingresos	73.6%
Rentabilidad financiera futura	38.5%
Cobertura de analistas	Low
Última actualización	27 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Here's Why We're Not Too Worried About Egetis Therapeutics' (STO:EGTX) Cash Burn Situation

May 26

Egetis Therapeutics AB (publ) (STO:EGTX) Is Expected To Breakeven In The Near Future

Mar 22

What Type Of Returns Would Egetis Therapeutics'(STO:EGTX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Feb 15

What You Need To Know About Egetis Therapeutics AB (publ)'s (STO:EGTX) Investor Composition

Jan 20

Egetis Therapeutics AB (publ) (STO:EGTX) Insiders Increased Their Holdings

Dec 24

Analyst Forecasts For PledPharma AB (publ) (STO:PLED) Are Surging Higher

Dec 03

When Will PledPharma AB (publ) (STO:PLED) Breakeven?

Dec 03

Previsiones de crecimiento de beneficios e ingresos

OM:EGTX - Estimaciones futuras de los analistas y datos financieros pasados (SEK Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	588	255	284	271	3
12/31/2025	514	125	60	111	5
12/31/2024	61	-289	-257	-256	4
3/31/2024	63	-327	-254	-254	N/A
12/31/2023	58	-327	-278	-278	N/A
9/30/2023	31	-318	-299	-299	N/A
6/30/2023	24	-286	-249	-249	N/A
3/31/2023	22	-240	-220	-220	N/A
12/31/2022	23	-194	-173	-173	N/A
9/30/2022	20	-148	-137	-137	N/A
6/30/2022	21	-113	-125	-125	N/A
3/31/2022	42	-114	-128	-128	N/A
12/31/2021	38	-104	-130	-130	N/A
9/30/2021	40	-147	-143	-143	N/A
6/30/2021	36	-153	-137	-137	N/A
3/31/2021	33	-155	-133	-133	N/A
12/31/2020	41	-178	-135	-135	N/A
9/30/2020	53	-127	-124	-124	N/A
6/30/2020	56	-134	-134	-134	N/A
3/31/2020	39	-127	-127	-127	N/A
12/31/2019	83	-61	-63	-63	N/A
9/30/2019	77	-61	-54	-54	N/A
6/30/2019	77	-48	-38	-38	N/A
3/31/2019	82	-46	-39	-39	N/A
12/31/2018	28	-85	-81	-81	N/A
9/30/2018	31	-95	-106	-106	N/A
6/30/2018	24	-103	-97	-97	N/A
3/31/2018	14	-91	-90	-90	N/A
12/31/2017	14	-88	N/A	-87	N/A
9/30/2017	N/A	-67	N/A	-51	N/A
6/30/2017	0	-48	N/A	-49	N/A
3/31/2017	N/A	-44	N/A	-41	N/A
12/31/2016	N/A	-38	N/A	-36	N/A
9/30/2016	N/A	-36	N/A	-36	N/A
6/30/2016	N/A	-39	N/A	-38	N/A
3/31/2016	N/A	-39	N/A	-44	N/A
12/31/2015	N/A	-44	N/A	-51	N/A
9/30/2015	N/A	-53	N/A	-55	N/A
6/30/2015	N/A	-53	N/A	-52	N/A
3/31/2015	N/A	-54	N/A	-47	N/A
12/31/2014	N/A	-48	N/A	-41	N/A
9/30/2014	N/A	-38	N/A	-34	N/A
6/30/2014	N/A	-31	N/A	-31	N/A
3/31/2014	N/A	-24	N/A	-25	N/A
12/31/2013	N/A	-26	N/A	-28	N/A
9/30/2013	N/A	-27	N/A	-29	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que EGTX sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (0.9%).

Beneficios vs. Mercado: Se prevé que EGTX sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que EGTX sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (67.1% al año) de EGTX crezcan más rápidamente que los del mercado Swedish (1.5% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (67.1% al año) de EGTX crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de EGTX sea alta dentro de 3 años (38.5%)

Egetis Therapeutics Crecimiento futuro

Future controles de criterios 6/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates decrease by 14%, EPS upgraded

Consensus EPS estimates upgraded to kr0.83 loss, revenue downgraded

Consensus revenue estimates increase by 25%

Price target increased by 11% to kr12.30

Price target decreased by 8.3% to kr13.30

Forecast breakeven date pushed back to 2025

Recent updates

Consensus revenue estimates decrease by 14%, EPS upgraded

Consensus EPS estimates upgraded to kr0.83 loss, revenue downgraded

Consensus revenue estimates increase by 25%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Financial position

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Egetis Therapeutics AB (publ) to Report First Half, 2024 Results on Aug 22, 2024

New minor risk - Share price stability

Price target increased by 11% to kr12.30

Egetis Therapeutics AB (publ) Provides Update on Disease Awareness and the Expanded Access Program for Tiratricol (Emcitate) in the USA

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Egetis Therapeutics AB (publ) to Report Q1, 2024 Results on May 03, 2024

Egetis Therapeutics AB (publ), Annual General Meeting, May 06, 2024

Egetis Therapeutics AB (publ) Announces Ema Validation of Marketing Authorisation Application for Emcitate for the Treatment of Mct8 Deficiency

Egetis Therapeutics AB (publ) Submits Marketing Authorisation Application for Emcitate for Treatment of MCT8 Deficiency to the European Medicines Agency

Egetis Therapeutics AB (publ) to Report Fiscal Year 2023 Results on Feb 24, 2024

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Egetis Therapeutics AB (Publ) Announces First Patient Included and Second Site Activated in the Pivotal Retriact Trial

Chief Executive Officer recently bought kr61k worth of stock

Price target decreased by 8.3% to kr13.30

Forecast breakeven date pushed back to 2025

Independent Director recently bought kr206k worth of stock

Director recently bought kr992k worth of stock

Consensus revenue estimates decrease by 14%, EPS upgraded

Price target decreased by 7.4% to kr14.50

Here's Why We're Not Too Worried About Egetis Therapeutics' (STO:EGTX) Cash Burn Situation

Egetis Terminates Discussions Regarding Potential Acquisition

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 13% to kr17.75

Forecast breakeven date pushed back to 2025

Consensus revenue estimates fall by 16%

Full year 2022 earnings released: kr1.00 loss per share (vs kr0.63 loss in FY 2021)

Egetis Therapeutics AB (Publ) Appoints Katayoun Welin-Berger as Vice President Operations, Effective from March 2023

Egetis Therapeutics AB (publ), Annual General Meeting, Apr 27, 2023

Consensus EPS estimates fall by 15%

We're Keeping An Eye On Egetis Therapeutics' (STO:EGTX) Cash Burn Rate

Egetis Therapeutics AB Submits Expanded Access Program for Emcitate® in the USA

Egetis Therapeutics AB (publ) to Report Fiscal Year 2022 Results on Feb 22, 2023

Less than half of directors are independent

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Egetis Therapeutics AB (publ) Receives Positive Opinion on Orphan Designation for Aladote® from the European Medicines Agency for the Prevention of Acute Liver Failure

Forecast breakeven date pushed back to 2024

Egetis Therapeutics AB (Publ) Appoints Sara Melton as President of North America

Egetis Therapeutics AB (Publ) Appoints Sara Melton as President of North America

Will Egetis Therapeutics (STO:EGTX) Spend Its Cash Wisely?

No longer forecast to breakeven

Egetis Therapeutics AB (Publ) Announces Executive Changes

Price target decreased to kr9.00

Less than half of directors are independent

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Egetis Therapeutics AB (Publ) Announces That the Recruitment Target Has Been Met in the Emcitate® Triac Trial II Study

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Egetis Therapeutics AB (publ) Secures Conditional Acceptance for Emcitate® as Brand Name in the US

Is Egetis Therapeutics AB (publ) (STO:EGTX) Trading At A 30% Discount?

Egetis Therapeutics AB (publ) Concludes Demonstrating Treatment Effects on T3 Levels in Mct8-Deficiency Could Provide Basis for Marketing Approval for Emcitate® in the Us

Egetis Therapeutics AB (Publ) Gets Notice of Intent to Grant for a New European Patent for a Combination Therapy with Aladote

Egetis Therapeutics AB (publ) Intends to Submit Marketing Authorisation Application for Emcitate® to the European Medicines Agency Based on Existing Clinical Data

Chief Executive Officer recently bought kr299k worth of stock

Third quarter 2021 earnings released: kr0.14 loss per share (vs kr0.46 loss in 3Q 2020)

Chief Financial Officer recently bought kr210k worth of stock

Egetis Receives Approval in Turkey for Compassionate Use of Emcitate® for MCT8 Deficiency

Chief Executive Officer recently bought kr55k worth of stock

Insider recently bought kr167k worth of stock

Second quarter 2021 earnings released: kr0.21 loss per share (vs kr0.68 loss in 2Q 2020)

Insider recently bought kr197k worth of stock

No longer forecast to breakeven